Assessment of hypertension control and clinical course of patients excluded from the SYMPLICITY HTN-3 trial.

The screening of patients referred for the Symplicity Renal-Denervation Catheter Therapy on Resistant Hypertension (SYMPLICITY HTN-3) trial was rigorous, with many found not eligible to participate. We investigate patients who were not included in the trial and evaluate their current hypertensive (HTN) therapy, control and clinical status. A retrospective review and telephone interview was performed 8-10 months postscreening on 45 patients and their referring providers who were ultimately not included.

Pharmacokinetics of anabolic steroids.

After an anabolic steroid is administered orally there is a rapid increase in its concentration in the blood in the following few hours. Excretion of the compound and its metabolites takes place via the urine and faeces, usually taking several days to completely pass through the system. Parenteral anabolic preparations, such as microcrystal suspensions, implants and solutions of nandrolone esters in a vegetable oil, are absorbed slowly.

Pharmacological studies with (7 alpha,17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14).

A novel steroid, (7 alpha,17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-yn-3-one (code name Org OD 14), was found to possess concomitant weak oestrogenic, androgenic and progestational activities. The effects observed in other tests, viz. inhibition of ovulation in rats, prevention of bone loss following ovariectomy in rats and restoration of sex drive in castrated male rats, corresponded to this hormonal profile.

Comparison of the receptor binding properties of nandrolone and testosterone under in vitro and in vivo conditions.

Previous in vitro binding studies with androgen receptors in rat seminal vesicles (Toth M. and Zakar T., J.

Enzymatic microdetermination of free fatty acids in plasma of animals using paraoxon to prevent lipolysis.

A simple, sensitive and rapid enzymatic method, manual as well as automated, is described for the determination of free fatty acids in plasma of animals. Spontaneous hydrolysis of esterified fatty acids present in the plasma samples is prevented by adding a specific lipase-esterase inhibitor.